-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-atai Life Sciences Announces Results From Phase 2A Trial Of Pcn-101 (R-Ketamine)

Reuters · 01/06/2023 07:14
BRIEF-atai Life Sciences Announces Results From Phase 2A Trial Of Pcn-101 (R-Ketamine)

- ATAI Life Sciences NV 9VC.F:

  • ATAI LIFE SCIENCES ANNOUNCES RESULTS FROM PHASE 2A TRIAL OF PCN-101 (R-KETAMINE) FOR TREATMENT-RESISTANT DEPRESSION

  • ATAI LIFE SCIENCES NV - PCN-101 WAS GENERALLY WELL-TOLERATED WITH RATES OF SEDATION AND DISSOCIATION COMPARABLE TO PLACEBO

  • ATAI LIFE SCIENCES NV - PCN-101 PHASE 2A CLINICAL TRIAL DID NOT MEET ITS PRIMARY ENDPOINT

  • ATAI LIFE SCIENCES -WILL WORK WITH UNIT PERCEPTION NEUROSCIENCE TO EXPLORE STEPS, INCLUDING BUT NOT LIMITED TO SEEKING STRATEGIC PARTNERSHIP OPTIONS

Source text for Eikon: ID:

Further company coverage: 9VC.F


((Reuters.Briefs@thomsonreuters.com;))